Research information only, not medical advice. Tirzepatide (Mounjaro, Zepbound) starts at 2.5 mg by subcutaneous injection once weekly and is titrated up to a maintenance dose of 5, 10 or 15 mg once weekly, per its FDA-approved label. This is the approved schedule for its indications, not medical advice.
Tirzepatide is FDA-approved as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management). Its label uses a stepwise schedule: 2.5 mg once weekly to start, titrated up to a maintenance dose of 5, 10 or 15 mg once weekly — the doses evaluated in the phase 3 trials. The gradual increase is used because gastrointestinal effects are greatest early in titration. This page reports the approved, studied doses, not a protocol to follow.
For the full evidence base, clinical trials, and regulatory status, see the Tirzepatide research overview . Related: tirzepatide side effects , tirzepatide before and after .
Sources
Frequently asked questions
- What is the tirzepatide dosage schedule?
- Per the FDA label, 2.5 mg once weekly to start, titrated up to a maintenance dose of 5, 10 or 15 mg once weekly. The exact schedule depends on the indication.
- What is the maximum dose of tirzepatide?
- The highest maintenance dose in the label and trials is 15 mg once weekly. This is the approved dose, not a recommendation.
Updated · sourced to primary documents